Author
Primary ORCID profile (0000-0002-7719-7783 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Mutual co-authors in cluster
9 papers
Recent·Most cited
C. R. M. Asquith, M. P. East, T. Laitinen, C. Alamillo-Ferrer, E. Hartikainen, C. I. Wells, A. D. Axtman, D. H. Drewry, G. J. Tizzard, A. Poso, T. M. Willson, G. L. Johnson
The paper identifies and optimizes narrow-spectrum TLK2 inhibitors using QSAR analysis and structural studies.
bioRxiv · Dec 28, 2023Pharmacology & Toxicology
A. J. Deen, S. Adinolfi, J. Harkonen, T. Patinen, X. Liu, T. Laitinen, P. Takabe, K. Kainulainen, S. Pasonen-Seppanen, L. Gawriyski, U. Thanigai Arasu, I. Selvarajan, P. Makinen, H. Laitinen, E. Kansanen, , A.-L. Levonen
This study shows that KEAP1 mutations in lung cancer activate TRAF2-NFκB signaling, enhancing cell survival by preventing apoptosis.
bioRxiv · Oct 10, 2023Cancer Biology
P. Medarametla, T. Laitinen, A. Poso
The paper compares X-ray and homology models of LsrK to assess their reliability for structure-based drug design targeting quorum sensing.
bioRxiv · Sep 3, 2020Biophysics
C. R. M. Asquith, G. J. Tizzard, J. M. Bennett, C. I. Wells, J. M. Elkins, T. M. M. Willson, A. Poso, T. Laitinen
This paper designs and tests 4-anilinoquinoline inhibitors targeting cyclin G-associated kinase (GAK) by analyzing water networks in the ATP binding site.
bioRxiv · Mar 6, 2020Biochemistry
C. R. M. Asquith, L. Temme, T. Laitinen, J. Pickett, F. E. Kwarcinski, P. Sinha, C. I. Wells, G. J. Tizzard, R. Zutshi, D. H. Drewry
The paper identifies 7-iodo-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine as a potent PKN3 inhibitor with an IC50 of 1.3 μM in cells, suggesting its potential as a tool for studying PKN3 biology and therapeutic applications.
bioRxiv · Mar 2, 2020 · PreprintPharmacology & Toxicology
C. R. M. Asquith, T. Laitinen, J. M. Bennett, C. I. Wells, J. M. Elkins, W. J. Zuercher, G. J. Tizzard, A. Poso
The paper designs and synthesizes 4-anilino-quin(az)oline compounds to analyze their kinase inhibition profiles and structure-activity relationships for GAK/SLK/STK10 targets.
bioRxiv · Sep 5, 2019Biochemistry
C. R. M. Asquith, K. A. Maffuid, T. Laitinen, C. D. Torrice, G. J. Tizzard, C. Alamillo-Ferrer, K. M. Koshlap, D. J. Crona, W. Zuercher
The paper designs and evaluates novel 4-anilinoquinolines and quinazolines as EGFR inhibitors, identifying a potent compound for lung cancer and chordoma treatment.
bioRxiv · Feb 11, 2019 · PreprintPharmacology & Toxicology
C. Asquith, K. Naegeli, M. P. East, T. Laitinen, T. M. Havener, C. I. Wells, G. L. Johnson, D. H. Drewry, W. J. Zuercher, D. C. Morris
The paper designs a set of GAK/EGFR inhibitors to study their relationship in chordoma and characterizes their activity in vitro and through target engagement assays.
bioRxiv · Nov 20, 2018Pharmacology & Toxicology
C. R. M. Asquith, T. Laitinen, J. M. Bennett, P. H. Godoi, G. J. Tizzard, J. M. Elkins, T. M. Willson, W. J. Zuercher
The paper identifies 4-anilinoquinolines as potent GAK inhibitors with high selectivity and suggests their potential as tools for studying GAK's role in infectious diseases.
bioRxiv · Apr 11, 2017Pharmacology & Toxicology